Market research
WANBURY.NSE Wanbury Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 8B
- P/E ratio
- 14.81
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.18
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE107F01022
- Market cap
- 8B
- P/E ratio
- 14.81
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.18
About
About Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. It offers formulations for anti-infectives, pain and analgesics, gastroenterology, rheumatology, respiratory, gynecology, and central nervous system, as well as for vitamins, minerals, and nutrition. The company also provides API products for antidiabetics, antidepressants, anti-histaminic, anaesthetic, anti-inflammatory, anti-coagulant, GERD, and gastric ulcer therapy, as well as antitussives and analgesics. Its API portfolio includes Metformin Hcl, Sertraline Hcl, Tramadol Hcl, Mefenamic Acid , Metformin Hcl DC, Diphenhydramine Citrate, Paroxetine, Diphenhydramine Hcl, and Anaesthetic API. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was founded in 1988 and is headquartered in Navi Mumbai, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the WANBURY.NSE discussion.
5 years, 5 months ago
Wanbury Limited is currently in a long term uptrend where the price is trading 23.7% above its 200 day moving average.
From a valuation standpoint, the stock is 87.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.6.
Wanbury Limited's total revenue rose by 13.2% to $1B since the same quarter in the previous year.
Its net income has increased by 378.0% to $59M since the same quarter in the previous year.
Finally, its free cash flow fell by 157.6% to $-82M since the same quarter in the previous year.
Based on the above factors, Wanbury Limited gets an overall score of 4/5.